SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C190 - Multiple Sclerosis Overview III: Basic and Translational Science

Event Time: Thursday April 27, 2017 7:00 am to 9:00 am
Topic(s): General Neurology, MS and CNS Inflammatory Disease
Director(s): Michael Racke MD
Description: Improved management of multiple sclerosis (MS) would result from understanding of MS pathogenesis, risk factors, immune abnormalities, and mechanism of action of MS treatments, including understanding of complications that can result from those treatments. Faculty will discuss new understanding in MS pathogenesis and how immune interventions can alter disease pathogenesis for an improved clinical outcome, and the mechanism of action of current MS therapies. This program complements C201: Multiple Sclerosis Overview: Clinical Pearls and C214: Multiple Sclerosis Overview: Clinical Advances, but covers independent topics.
Completion Message: Participants should be able to identify steps in MS pathogenesis, treatments used in MS management, and how approved therapies affect the immune response and potential complications resulting from those interventions.
CME Credits: 2
Core Competencies: Patient Care, Medical Knowledge

Program Speakers - Tentative

Start/End Time Title Faculty
7:00 AM - 7:45 AM MS Pathogenesis Olaf Stuve MD, PhD, FAAN 
7:45 AM - 8:30 AM Mechanism of MS Therapies and Their Use Michael Racke MD 
8:30 AM - 9:00 AM Questions and Answers Faculty 


Speaker Disclosure
Michael K. Racke, MD Dr. Racke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Coherus Bioscience;Teva Neuroscience;. Dr. Racke has received personal compensation in an editorial capacity for Elsevier as Editor-in-Chief of Journal of Neuroimmunology. Dr. Racke has received research support from Genentech; Novartis; Actelion; TG Therapeutics; Alkermes.

Olaf Stuve, MD, PhD, FAAN Dr. Stuve has received personal compensation for activities with Novartis and Sanofi Genzyme. Dr. Olaf Stuve has received personal compensation in an editorial capacity for JAMA Neurology, Multiple Sclerosis Journal, and Therapeutic Advances in Neurological Disorders.. Dr. Stuve has received research support from Teva Pharmaceuticals and Opexa Therapeutics.

Register Now

Related Courses

Wednesday April 25, 2018

7:00 AM-9:00 AM
C136 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
C139 Neurologic Case Studies in Pregnancy Mary O'Neal MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C144 Neurology Update I: Epilepsy, Behavioral Neurology, and Neurologic Infections Ralph Jozefowicz MD, FAAN
C147 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
C148 LGBTQI Health in Neurology Holly Hinson MD, MCR
3:30 PM-5:30 PM
C160 Neurology Update II: Movement Disorders, Spine Disorders, and Sleep Disorders Ralph Jozefowicz MD, FAAN
C162 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD
C168 CNS Toxicities Neeraj Kumar MD


Forgot Password?